Klotho Peptide — Indexed Studies

Diagnostic Delays and Patient Experiences in Erythropoietic Protoporphyria: A Multi-Site Study in Australia.

Bell F, Robertson S, Ross G

Hematopoietic stem cell transplantation for erythropoietic porphyria-induced acute liver failure: a case report and literature review.

Merati M, Shimano KA, Kim GE et al.

Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

Seidl-Philipp M, Schratter H, Auer J et al.

Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.

Shetty N, Quiñonez RL, Ceresnie MS et al.

Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report.

Peshin S, Takrori E, Khan KS et al.

Key role of Levitt's carbon monoxide breath test in revealing coexistent Gilbert syndrome and erythropoietic protoporphyria: A case report.

Kang LL, Zhang HD

From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.

Minder AE, Barman-Aksözen J

An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria.

Ross G, Stewart P, Mensing G et al.

New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.

Dechant C, Wäscher S, Granata F et al.

Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial.

Yeung AK, Bonkovsky HL, Balwani M et al.

Letter to the Editor - Qualitative evidence submitted by patients to NICE: need for more quality or unrealistic and unfair requirements?

Falchetto R, Barman-Aksözen J

Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis.

DerSarkissian M, Norregaard C, Romdhani H et al.

Challenges in the pathological diagnosis of erythropoietic protoporphyria: a case report.

Yang T, Chen C, Li C et al.

Impact of delay in diagnosis in patients with erythropoietic protoporphyria: A cross-sectional survey study.

Tran B, Raef H, Rebeiz L et al.

Remission of erythropoietic protoporphyria (EPP) during pregnancy - Experience of two patients.

Paul G, Angelika H

Jaundice in an Adult Female Patient With Photosensitivity.

Falcón-Antonio OE, Aguirre-Villarreal D, Martínez-Sánchez FD et al.

Erythropoietic protoporphyria linked to intricate double heterozygous mutations in theFECH gene: a case report and literature review.

Xiong H, He S, Yang Z et al.

Biological Variation of Erythrocyte Total, Metal-Free, and Zinc Protoporphyrin IX in Patients with Erythropoietic Protoporphyria and Healthy Subjects: Implications for Clinical Interpretation and Monitoring.

Lillemoen PKS, Fauskanger PK, Sandberg S et al.

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).

Homey B, Schelonke K, Schlegel CM et al.

Long-term iron supplementation in four patients with X-linked erythropoietic protoporphyria: associations with serum proteins and erythrocyte protoporphyrin levels-a single-centre retrospective study.

Minder AE, Granata F, van Breemen F et al.

Case Report: Cholestatic liver disease in the course of erythropoietic protoporphyria associated with renal hypodysplasia and atrial septal defect.

Lipiński P, Lipniacka A, Klaudel-Dreszler M et al.

Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria.

Levy C, Naik H, Overbey J et al.

Paternal Split-Liver Transplantation Followed by Haploidentical Hematopoietic Cell Transplantation in an Adult Patient With Protoporphyria-Induced Liver Failure.

Stölzel U, Jost L, Seehofer D et al.

Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria.

Silver SM, Houghton K, Hitchens A et al.

Correction: Erythropoietic protoporphyria: case reports for clinical and therapeutic hints.

Tumminelli C, Burlo F, Pastore S et al.

Case report: Xeroderma pigmentosum Group A with erythropoietic protoporphyria in a young Chinese patient.

Wu SH, Xiao T, Zhao D et al.

When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome-18 deletion.

Rovaris S, La Rosa G, Mezzana S et al.

Successful treatment of severe hepatic impairment in erythropoietic protoporphyria: A case report and review of literature.

Zeng T, Chen SR, Liu HQ et al.

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist.

Ogasawara A, Ide R, Inoue S et al.

Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.

Rhodes LE

Observational pilot study of multi-wavelength wearable light dosimetry for erythropoietic protoporphyria.

Dickey AK, Berkovich J, Leaf RK et al.

Diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and x-linked protoporphyria: A patient-friendly summary of the 2023 evidence-based consensus guidelines.

Mann AK, Allan L, Wheeden KP et al.

Development and Content Validation of Novel Patient-Reported Outcome Measures to Assess Disease Severity and Change in Patients with Erythropoietic Protoporphyria: The EPP Impact Questionnaire (EPIQ).

Mathias SD, Burke L, Colwell HH et al.

Management of erythropoietic protoporphyria with cholestatic liver disease: A case report.

Poli A, Frieri C, Lefebvre T et al.

Erythropoietic protoporphyria: case reports for clinical and therapeutic hints.

Tumminelli C, Burlo F, Pastore S et al.

Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria.

Mathias SD, Burke L, Colwell HH et al.

Erythropoietic protoporphyria and afamelanotide: a patient's perspective.

O'Reilly M, McGuire VA, Dawe RS

Consecutive Liver and Bone Marrow Transplantation for Erythropoietic Protoporphyria: Case Report and Literature Review.

Portich JP, Ribeiro AS, Rodrigues Taniguchi AN et al.

Living-Donor Liver Transplantation for Erythropoietic Protoporphyria: A Case Report and Literature Review.

Ogasawara H, Tokodai K, Nakanishi W et al.

Comment on "Liver involvement in patients with erythropoietic protoporphyria".

Cheema MRS

Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist.

Ogasawara A, Ogawa K, Ide R et al.

Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study.

Barman-Aksözen J, Minder AE, Granata F et al.

Dersimelagon in Erythropoietic Protoporphyrias.

Balwani M, Bonkovsky HL, Levy C et al.

Overview of Liver Involvement in Patients With Erythropoietic Protoporphyria.

Levy C

The Oral Bioavailability and Effect of Various Gastric Conditions on the Pharmacokinetics of Dersimelagon in Healthy Adult Volunteers.

Ogawa K, Ide R, Belongie K et al.

Protection against visible light by dihydroxyacetone in erythropoietic protoporphyria.

Heerfordt IM, Philipsen PA, Lerche CM et al.

Prospective observational pilot study of quantitative light dosimetry in erythropoietic protoporphyria.

Dickey AK, Rebeiz L, Raef H et al.

Recovery From Severe Systemic Peripheral Neuropathy Secondary to Erythropoietic Protoporphyria by Liver Transplant: A Case Report.

Shizuku M, Kurata N, Jobara K et al.

A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria.

Balwani M, Naik H, Overbey JR et al.

Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study.

Ceresnie MS, Mohney L, Ko D et al.

Heme Biosynthetic Gene Expression Analysis With dPCR in Erythropoietic Protoporphyria Patients.

Granata F, Brancaleoni V, Barman-Aksözen J et al.

Single-incision laparoscopic partial cecectomy for appendiceal mucocele in a patient with porphyria photosensitivity.

Takami T, Itatani Y, Shibuya R et al.

Protection from phototoxic injury during laparoscopic surgery in patients with erythropoietic protoporphyria.

Pielaciński K, Kwasny M, Górski W et al.

Diagnosis and treatment of icteric hepatitis caused by erythropoietic protoporphyria: A case report.

Huang H, Cai L, Li X et al.

Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study.

Wensink D, Wagenmakers MAEM, Qi H et al.

Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.

Minder AE, Barman-Aksoezen J, Schmid M et al.

Liver involvement in patients with erythropoietic protoporphyria: retrospective analysis of clinicopathological features of 5 cases.

Zhao C, Guan JX, Hui DY et al.

Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag.

Jiang Z, Jiang X, Chen M

The effect of vitamin D recommendations on serum 25-hydroxyvitamin D level in patients with erythropoietic protoporphyria.

Heerfordt IM, Lerche CM, Philipsen PA et al.

ABCB6 polymorphisms are not overly represented in patients with porphyria.

Farrell CP, Nicolas G, Desnick RJ et al.

Liver involvement in patients with erythropoietic protoporphyria.

Wensink D, Coenen S, Wilson JHP et al.

Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL.

Biolcati G, Hanneken S, Minder EI et al.

Algorithm-based readability assessment of online patient educational material for erythropoietic protoporphyria.

Kulkarni V, Varghese J, Gamsarian V et al.

Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL.

Biolcati G, Hanneken S, Minder EI et al.

Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients.

Wang YM, Gloude NJ, Davies SM et al.

Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.

Wensink D, Langendonk JG, Overbey JR et al.

Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.

Arisi M, Rossi M, Rovati C et al.

Alternative Pathway Involvement in Protoporphyria Patients Related to Sun Exposure.

Granata F, Duca L, Brancaleoni V et al.

A mutation in the iron-responsive element of ALAS2 is a modifier of disease severity in a patient suffering from CLPX associated erythropoietic protoporphyria.

Ducamp S, Luscieti S, Ferrer-Cortès X et al.

Hematopoietic cell transplant for reversal of liver fibrosis in a pediatric patient with erythropoietic protoporphyria.

Hashmi SK, Harstead E, Sachdev M et al.

Surgical treatment for breast cancer in a patient with erythropoietic protoporphyria and photosensitivity: a case report.

Shimazaki A, Hashimoto T, Kai M et al.

Light-provoked skin symptoms on the hands of erythropoietic protoporphyria patients related to personal dosimeter measurements, skin symptoms, light protection and priming.

Heerfordt IM, Heydenreich J, Philipsen PA et al.